

15 January 2026

Researching the incidence and treatment of endometrial cancer.

Q1. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments?

- **Dostarlimab (Jemperli) <5**
- **Dostarlimab (Jemperli) AND Chemotherapy <5**
- **Hormone therapy (Progesterone or Letrozole) Not available on RISOH**
- **Pembrolizumab (Keytruda) monotherapy <5**
- **Lenvatinib + Pembrolizumab (Lenvima +Keytruda) <5**
- **Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) 26**
- **Any other SACT Any other Chemotherapy Pacliatxel <5**
- **Durvalumab with platinum-based chemotherapy <5**
- **Pembrolizumab with platinum-based chemotherapy <5**

Q2. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments?

- **Dostarlimab (Jemperli) AND Chemotherapy <5**
- **Durvalumab with platinum-based chemotherapy <5**
- **Pembrolizumab with platinum-based chemotherapy <5**
- **Hormone therapy (Progesterone or Letrozole) Not available on RISOH**
- **Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) 15**
- **Any other SACT Any other chemotherapy <5**

Q3. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

At present there are no clinical trials specific to endometrial cancer open for recruitment.

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.